Pionyr has a deep and diversified pipeline of myeloid targeting monoclonal antibody therapeutics. The PY314 and PY159 programs, targeting TREM2 and TREM1 respectively, have been cleared by the FDA to initiate clinical trials. Pionyr’s earlier stage programs range in maturity from target validation to development candidate stage. All programs are anticipated to be the first therapeutics in the clinic to address their respective targets.
Pionyr’s Myeloid Tuning™ technology builds on the discovery that altering the tumor microenvironment to favor immune-activating cells over immune-suppressing cells enhances the body’s ability to combat cancer. Pionyr’s lead programs PY314 and PY159 “tune” the tumor myeloid infiltrate in distinct and impactful ways. PY314 targets for selective depletion of a subset of tumor associated macrophages (TAMs) that express surface receptor TREM2. Depleting TREM2 positive TAMs clears the way for activated T-cells and pro-inflammatory myeloid cells to take control of the TME and destroy tumor cells. PY159 has a distinct mechanism of action whereby it targets for cellular “reprogramming” TREM1 positive immunosuppressive monocytes, neutrophils and macrophages. Upon PY159 binding to TREM1 on these cells, intracellular signaling shifts these cells into pro-inflammatory states leading to tumor cell destruction. By targeting cellular subsets distinct to those of to approved checkpoint inhibitors (CPIs), Pionyr’s Myeloid Tuning™ therapies represent an orthogonal and potentially synergistic approach to treatment with CPIs.